Study guide

33.3 Vasoconstrictors, Maximum Doses and Systemic Toxicity

Overseas Registration Examination ORE

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: ORE Part 1 — Exam Blueprint, Logistics and Strategy

1.1 Structure and Format of ORE Part 1 1.2 The Official Blueprint and Preparing for Practice 1.3 Eligibility, Fees, Attempts and Time Limits

2 Chapter 2: Anatomy of the Head and Neck

2.1 The Trigeminal Nerve and Dental Innervation 2.2 The Facial Nerve and Parotid Region 2.3 The Temporomandibular Joint and Muscles of Mastication 2.4 The Infratemporal Fossa and Spread of Odontogenic Infection

3 Chapter 3: Dental Anatomy, Morphology and Occlusion

3.1 Permanent and Primary Tooth Morphology 3.2 Functional Occlusion: Centric Relation, Guidance and Interferences 3.3 Classifying Occlusion: Angle and BSI Incisor Relationships

4 Chapter 4: Genetics, Embryology and Odontogenesis

4.1 Stages of Odontogenesis and Molecular Signalling 4.2 Amelogenesis and Enamel Microstructure 4.3 Dentinogenesis and the Pulp-Dentine Complex 4.4 Cementum, the Periodontal Ligament and Oral Mucosa 4.5 Genetic and Developmental Dental Anomalies

5 Chapter 5: Oral Biology and Salivary Physiology

5.1 Salivary Gland Anatomy, Microarchitecture and Innervation 5.2 Salivary Secretion, Flow Rates and Autonomic Control 5.3 Salivary Buffering Systems and Protective Macromolecules 5.4 Physiology of Mastication and Deglutition 5.5 Taste, Lingual Papillae and Gustatory Pathways 5.6 Xerostomia, Sjogren's Syndrome and Salivary Diagnostics

6 Chapter 6: Physiology of the Major Body Systems

6.1 Cardiovascular and Respiratory Physiology 6.2 Renal, Endocrine and Gastrointestinal Physiology 6.3 Haematology and Haemostasis 6.4 Neurophysiology, Pain and the Autonomic Nervous System

7 Chapter 7: Bone Biology, Calcium Homeostasis and Healing

7.1 Microstructure and Architecture of Alveolar Bone 7.2 Bone Remodelling and the RANK/RANKL/OPG Axis 7.3 Endocrine Control of Calcium and Phosphate 7.4 Extraction Socket Healing and Ridge Resorption 7.5 Impaired Healing: MRONJ, Osteoradionecrosis and Systemic Risk

8 Chapter 8: Oral Microbiology and Biofilm Ecology

8.1 The Oral Microbiome and Biofilm Development 8.2 Cariogenic Microbiology: Mutans Streptococci and Lactobacilli 8.3 Ecological Hypotheses of Dental Caries 8.4 Biofilm Tolerance and the Case for Mechanical Plaque Control

9 Chapter 9: Immunology Relevant to Oral Disease

9.1 Innate Mucosal Immunity and Gingival Crevicular Fluid 9.2 Cellular Immunity in the Periodontium 9.3 Microbial Pathogenesis: Complexes and Keystone Pathogens 9.4 Host-Mediated Tissue Destruction 9.5 Hypersensitivity Reactions in Dental Practice 9.6 Autoimmune Mucocutaneous Bullous Disease 9.7 Immunodeficiency and Oral HIV Manifestations

10 Chapter 10: General Pathology and Neoplasia

10.1 Cellular Adaptation and Mechanisms of Cell Death 10.2 Inflammation, Wound Healing and Repair 10.3 Principles of Neoplasia and Carcinogenesis 10.4 TNM Staging of Oral Cavity Carcinoma

11 Chapter 11: Statistics and Research Methods

11.1 Study Designs and the Hierarchy of Evidence 11.2 Descriptive and Inferential Statistics 11.3 Diagnostic Test Performance 11.4 Critical Appraisal, Bias and Research Governance

12 Chapter 12: Human Disease: Cardiovascular and Respiratory

12.1 Infective Endocarditis and NICE CG64 12.2 Hypertension and Blood Pressure Thresholds for Dental Care 12.3 Angina, Myocardial Infarction and Antiplatelet Therapy 12.4 Asthma, COPD and Respiratory Emergencies

13 Chapter 13: Human Disease: Endocrine, Haematological and Renal

13.1 Diabetes Mellitus and the Periodontal Axis 13.2 Congenital Bleeding and Clotting Disorders 13.3 Anticoagulants and Antiplatelets: The SDCEP Protocol 13.4 Chronic Kidney Disease and Haemodialysis

14 Chapter 14: Human Disease: Gastrointestinal, Hepatic and Neurological

14.1 Gastrointestinal Disease and Intrinsic Dental Erosion 14.2 Liver Disease, Coagulopathy and Viral Hepatitis 14.3 Epilepsy, Stroke and Transient Ischaemic Attack 14.4 Trigeminal Neuralgia, Bell's Palsy and Giant Cell Arteritis

15 Chapter 15: Oral Aspects of Human Disease

15.1 Oral Manifestations of Systemic Disease 15.2 Orofacial Pain and Temporomandibular Disorders 15.3 Dry Mouth, Altered Taste and Halitosis

16 Chapter 16: Infection Prevention and Control

16.1 The Decontamination Cycle, Sterilization and Waterlines 16.2 Routes of Transmission and Blood-Borne Viruses

17 Chapter 17: Dental Materials

17.1 Dental Amalgam: Metallurgy and UK Regulation 17.2 Resin Composites: Chemistry and Placement 17.3 Dental Adhesive Systems 17.4 Acid Etching, the Hybrid Layer and MMP Degradation 17.5 Glass Ionomer Cements, RMGICs and Compomers 17.6 Impression Materials and Digital Scanning 17.7 Luting Cements and Adhesive Conditioning Protocols 17.8 Dental Ceramics and Cast Alloys 17.9 Gypsum Products, Waxes and Denture Base Polymers

18 Chapter 18: Behavioural Sciences Relevant to Oral Health Care

18.1 Health Behaviour Models and Behaviour Change 18.2 Dental Anxiety and Phobia 18.3 Psychosocial and Sociological Determinants of Oral Health

19 Chapter 19: Patient Assessment and Diagnosis

19.1 History Taking and Clinical Examination 19.2 Special Investigations and Reaching a Diagnosis

20 Chapter 20: Treatment Planning and Risk-Based Care

20.1 Treatment Planning and Sequencing 20.2 Risk Assessment, Recall Intervals and Preventive Planning

21 Chapter 21: Cariology and Caries Risk Assessment

21.1 Caries Pathogenesis and the Stephan Curve 21.2 Histopathology of Enamel and Dentinal Caries 21.3 Caries Diagnosis, ICDAS and Risk Assessment

22 Chapter 22: Operative Dentistry and Minimal Intervention

22.1 Minimal Intervention and Selective Caries Removal 22.2 Pulp Vitality Assessment and Biological Pulp Capping 22.3 Cavity Design, the C-Factor and Margin Geometry

23 Chapter 23: Endodontics

23.1 Pulp Histology and the Low-Compliance Environment 23.2 Pulpal Neurophysiology and Dentine Hypersensitivity 23.3 Pulpal and Periapical Diagnostic Terminology 23.4 Endodontic Diagnostic Testing 23.5 Access Cavity Design and Canal Configurations 23.6 Working Length Determination and Canal Preparation 23.7 Chemical Disinfection and Irrigant Activation 23.8 Medicaments, Obturation Materials and Techniques 23.9 Restoring Endodontically Treated Teeth 23.10 Endodontic Emergencies, Cracked Teeth and Root Fracture

24 Chapter 24: Periodontology

24.1 The 2018 Classification and Periodontal Health 24.2 Plaque-Induced and Non-Plaque-Induced Gingival Disease 24.3 Staging and Grading Periodontitis 24.4 Peri-Implant Disease and Systemic Risk Factors 24.5 The Basic Periodontal Examination 24.6 Simplified BPE in Children and Full Periodontal Charting 24.7 Furcation Involvement, Mobility and Occlusal Trauma 24.8 The BSP Stepwise Treatment Framework 24.9 Periodontal Instrumentation and Healing 24.10 Re-Evaluation, Endpoints and Periodontal Surgery 24.11 Crown Lengthening, Supracrestal Attachment and Supportive Care

25 Chapter 25: Fixed Prosthodontics

25.1 Biomechanical Principles of Tooth Preparation 25.2 Margin Design and the Supracrestal Attachment 25.3 Bridge Design and Resin-Bonded Bridges 25.4 Gingival Retraction, Provisionals and Temporary Cements

26 Chapter 26: Removable Prosthodontics

26.1 Removable Partial Dentures: Classification, Design and Surveying 26.2 Complete Dentures: Principles, Impressions and Jaw Registration

27 Chapter 27: Paediatric Dentistry

27.1 Primary Tooth Anatomy and Caries Management Strategies 27.2 Preformed Metal Crowns and the Hall Technique 27.3 Pulp Therapy in Primary Teeth 27.4 Extractions in the Primary Dentition 27.5 Non-Pharmacological Behaviour Management 27.6 Inhalation Sedation in Paediatric Dentistry 27.7 The Developing Dentition and Space Management 27.8 Serial Extraction and Non-Nutritive Sucking Habits

28 Chapter 28: Dental Traumatology

28.1 Trauma Assessment and Fractures of Permanent Teeth 28.2 Luxation Injuries, Avulsion and Replantation 28.3 Primary Tooth Trauma and Splinting Specifications

29 Chapter 29: Orthodontics

29.1 Extraoral Orthodontic Assessment 29.2 Intraoral Occlusal Assessment 29.3 Skeletal Pattern and Cephalometric Analysis 29.4 IOTN and NHS Treatment Eligibility 29.5 Upper Removable Appliances 29.6 Functional and Fixed Appliances 29.7 Biology of Orthodontic Tooth Movement 29.8 Orthodontic Risks and Retention

30 Chapter 30: Oral Surgery

30.1 Exodontia Biomechanics and Instrument Selection 30.2 Surgical Flap Design, Bone Removal and Suturing 30.3 Third Molar Surgery and NICE Guidance 30.4 Dry Socket and Oroantral Communication 30.5 Odontogenic Infection and Fascial Space Spread

31 Chapter 31: Oral Medicine

31.1 Recurrent Aphthous Stomatitis 31.2 Oral Candidiasis 31.3 Viral Oral Infections 31.4 Reactive Soft Tissue Lesions and the Epulides 31.5 Oral Potentially Malignant Disorders 31.6 Oral Squamous Cell Carcinoma, Urgent Referral and Biopsy

32 Chapter 32: Oral Pathology

32.1 Odontogenic and Non-Odontogenic Cysts 32.2 Odontogenic Tumours 32.3 Obstructive and Reactive Salivary Gland Disease 32.4 Salivary Gland Neoplasms

33 Chapter 33: Therapeutics and Prescribing

33.1 Local Anaesthetic Chemistry and Mechanism of Action 33.2 UK Local Anaesthetic Formulations 33.3 Vasoconstrictors, Maximum Doses and Systemic Toxicity 33.4 Analgesics for Acute Dental Pain 33.5 Antimicrobial Stewardship and First-Line Regimens 33.6 Antifungal and Antiviral Therapeutics

34 Chapter 34: Medical Emergencies in Dental Practice

34.1 The ABCDE Approach and the Emergency Drug Kit 34.2 Anaphylaxis and Acute Coronary Syndrome 34.3 Hypoglycaemia, Acute Asthma and Seizures 34.4 Syncope, Adrenal Crisis, Choking and Resuscitation

35 Chapter 35: Dental Radiology and Radiation Protection

35.1 Radiation Physics, Filtration and Collimation 35.2 Intraoral, Bitewing and Occlusal Projections 35.3 Dental Panoramic Tomography: Principles, Positioning and Errors 35.4 Lateral Cephalometry and Cone Beam CT 35.5 Systematic Reporting and Radiographic Caries Diagnosis 35.6 Radiology of Periodontal Bone Loss and Jaw Lesions 35.7 Radiographic Quality Assurance 35.8 IRR17 and IR(ME)R 2017

36 Chapter 36: Special Care Dentistry and Conscious Sedation

36.1 Special Care Dentistry, Risk Stratification and Sedation Principles 36.2 Inhalation Sedation with Nitrous Oxide 36.3 Intravenous Sedation with Midazolam 36.4 Oral Sedation and General Anaesthesia Referral

37 Chapter 37: Dental Public Health

37.1 Delivering Better Oral Health and the Fluoride Toolkit 37.2 Oral Health Epidemiology and Indices 37.3 Inequalities, Water Fluoridation and Population Prevention 37.4 NHS Dental Services, Access and Commissioning

38 Chapter 38: Communication and Interpersonal Skills

38.1 Patient Communication and Shared Decision-Making 38.2 Breaking Bad News, Complaints and the Duty of Candour 38.3 Referrals, Records and Communication with the Team

39 Chapter 39: Consent and Capacity

39.1 Valid Consent and the Montgomery Standard 39.2 The Mental Capacity Act 2005 39.3 Best Interests Decisions and Lasting Power of Attorney 39.4 Consent in Children and Young People 39.5 Safeguarding Children and Vulnerable Adults 39.6 Confidentiality, Data Protection and Lawful Disclosure

40 Chapter 40: Clinical Professionalism and the GDC

40.1 The General Dental Council and Standards Principles 1 to 4 40.2 GDC Standards: Principles 5 to 9 40.3 The GDC Fitness to Practise Process 40.4 Clinical Governance and the Audit Cycle

41 Chapter 41: Health and Safety Law in Dental Practice

41.1 Health and Safety Legislation, COSHH, RIDDOR and Sharps

42 Chapter 42: Self-Management and Professional Development

42.1 Enhanced CPD, Lifelong Learning and Reflective Practice 42.2 Managing Time, Stress and Clinical Wellbeing 42.3 Leadership, Delegation and Practice Management

33.3 Vasoconstrictors, Maximum Doses and Systemic Toxicity

Key Takeaways Explain This Topic AI

The maximum adrenaline dose for a healthy adult is 0.2 mg, which is about 7.2 cartridges of 1:80,000 or 9 cartridges of 1:100,000 at 2.2 mL.

For a cardiovascularly compromised adult the maximum is restricted to 0.04 mg, roughly 1.5 cartridges of 1:80,000.

The maximum safe dose of lidocaine with adrenaline is 4.4 mg/kg, capped at 300 mg in adults.

Dose limits must be calculated on body weight for children, never on adult cartridge counts.

Early systemic toxicity causes circumoral tingling, tinnitus, metallic taste and confusion, then convulsions before cardiovascular depression.

Last updated: September 2026

Vasoconstrictors in Dental Anaesthesia

Vasoconstrictors are included in dental local anaesthetic solutions to counteract the intrinsic vasodilatory actions of local anaesthetic bases (especially lidocaine and procaine). They provide four major clinical benefits:

Prolonged Duration: Constriction of local arterioles delays vascular clearance, maintaining the drug around nerve fibres.

Enhanced Pulpal Depth: Increases the concentration of anaesthetic molecules reaching the inner core fibres of the nerve trunk.

Reduced Peak Plasma Concentrations: Slower systemic absorption lowers the risk of systemic toxicity (LAST).

Surgical Haemostasis: Decreases intraoperative haemorrhage in the surgical field.

Adrenaline (Epinephrine) Receptor Pharmacology

Adrenaline is an endogenous catecholamine that acts as a potent, non-selective agonist across adrenergic receptor subtypes: Adrenaline (Epinephrine)

  • │
  • ┌────────────────────────────┼────────────────────────────┐
  • ▼ ▼ ▼
  • Alpha-1 (α1) Receptors Beta-1 (β1) Receptors Beta-2 (β2) Receptors
  • Submucosal vasoconstriction - Positive inotropy (force) - Skeletal arteriolar dilation
  • Local surgical haemostasis - Positive chronotropy (rate)- Bronchodilation
  • Reduced systemic uptake - Increased cardiac output - Lowers diastolic BP
  • Elevated myocardial MVO2
  • Maximum Safe Dosage Guidelines

Adrenaline Thresholds:

Healthy Adult Patient: Maximum recommended dose is 0.2 mg (200 micrograms) per appointment.

For 1:80,000 adrenaline ( 12.5 mcg/mL 12.5\text{ mcg/mL} 12.5 mcg/mL ), 0.2 mg corresponds to 16.0 mL 16.0\text{ mL} 16.0 mL , or 7.2 UK cartridges (2.2 mL) . In practice, this is rounded to a safe maximum of 7 to 8 cartridges .

For 1:100,000 adrenaline ( 10.0 mcg/mL 10.0\text{ mcg/mL} 10.0 mcg/mL ), 0.2 mg corresponds to 20.0 mL 20.0\text{ mL} 20.0 mL , or 9 UK cartridges (2.2 mL) .

Cardiovascular Patient (ASA III/IV, Ischaemic Heart Disease, Uncontrolled Arrhythmia): Maximum recommended dose is restricted to 0.04 mg (40 micrograms) .

For 1:80,000 adrenaline, 0.04 mg corresponds to 3.2 mL 3.2\text{ mL} 3.2 mL , representing 1.45 cartridges (strictly capped at maximum 1.5 to 2 cartridges ).

Local Anaesthetic Base Dosage Limits:

Lidocaine (with adrenaline): The figure taught for UK dental practice is 4.4 mg/kg of body weight, up to an absolute ceiling of 300 mg in adults. Note that maximum-dose figures for lidocaine differ between sources — the BNF and the manufacturer's summary of product characteristics support a higher ceiling of 7 mg/kg up to 500 mg — so quote the conservative dental figure and calculate from body weight. In a healthy adult the adrenaline limit is reached first in any case.

Articaine (with adrenaline): Maximum safe dose is 7.0 mg/kg of body weight, up to an absolute ceiling of 500 mg in adults.

Mepivacaine plain: Maximum safe dose is 4.4 mg/kg , up to an absolute ceiling of 400 mg .

Prilocaine (with felypressin): Maximum safe dose is 6.0 mg/kg , up to an absolute ceiling of 400 mg .

Step-by-Step Clinical Calculation Examples

  • Note
  • Worked Example 1: 70 kg Healthy Adult (2% Lidocaine with 1:80,000 Adrenaline)

Calculate base limit: 70 kg × 4.4 mg/kg = 308 mg 70\text{ kg} \times 4.4\text{ mg/kg} = 308\text{ mg} 70 kg × 4.4 mg/kg = 308 mg , which is capped by the 300 mg adult ceiling.

Determine drug content per cartridge: A 2.2 mL cartridge of 2% lidocaine contains 20 mg/mL × 2.2 mL = 44 mg 20\text{ mg/mL} \times 2.2\text{ mL} = 44\text{ mg} 20 mg/mL × 2.2 mL = 44 mg .

Calculate maximum cartridges based on lidocaine: 300 mg ÷ 44 mg/cartridge = 6.8 cartridges 300\text{ mg} \div 44\text{ mg/cartridge} = 6.8\text{ cartridges} 300 mg ÷ 44 mg/cartridge = 6.8 cartridges , so 6 whole cartridges.

Check adrenaline limit: 6 cartridges contain 6 × 27.5 mcg = 165 mcg = 0.165 mg 6 \times 27.5\text{ mcg} = 165\text{ mcg} = 0.165\text{ mg} 6 × 27.5 mcg = 165 mcg = 0.165 mg , safely below the 0.2 mg (200 mcg) healthy-adult threshold.

Safe Clinical Limit: 6 cartridges on the conservative dental figure; the adrenaline ceiling of 0.2 mg would permit at most 7.

  • Warning
  • Worked Example 2: 20 kg Child (2% Lidocaine with 1:80,000 Adrenaline)

Calculate base limit: 20 kg × 4.4 mg/kg = 88 mg 20\text{ kg} \times 4.4\text{ mg/kg} = 88\text{ mg} 20 kg × 4.4 mg/kg = 88 mg .

Determine cartridges: 88 mg ÷ 44 mg/cartridge = 2.0 cartridges 88\text{ mg} \div 44\text{ mg/cartridge} = 2.0\text{ cartridges} 88 mg ÷ 44 mg/cartridge = 2.0 cartridges .

Check adrenaline: 2 × 27.5 mcg = 55 mcg = 0.055 mg 2 \times 27.5\text{ mcg} = 55\text{ mcg} = 0.055\text{ mg} 2 × 27.5 mcg = 55 mcg = 0.055 mg (well below childhood systemic threshold).

Safe Clinical Limit: Exactly 2 cartridges (4.4 mL). A third cartridge would give 132 mg, or 6.6 mg/kg, exceeding the recommended maximum for this child and moving the dose towards the range in which systemic toxicity becomes a real risk.

Local Anaesthetic Systemic Toxicity (LAST)

Local Anaesthetic Systemic Toxicity (LAST) is a life-threatening adverse event triggered by an excessive plasma concentration of free local anaesthetic. It most commonly results from inadvertent direct intravascular injection due to failure to aspirate in two planes, or from exceeding maximum weight-adjusted dosage limits.

Pathophysiological Cascade

Local anaesthetic bases are lipophilic and rapidly cross the blood-brain barrier. In the central nervous system, they initially block inhibitory cortical interneurons (GABAergic pathways), releasing unopposed excitatory pathways. As plasma levels continue to climb, both inhibitory and excitatory pathways are suppressed, producing generalized central nervous system depression. Concurrently, high plasma concentrations block cardiac sodium channels ( N a v 1.5 Na_v 1.5 N a v ​ 1.5 ), uncoupling cardiac excitation-contraction and precipitating lethal conduction blocks and refractory arrhythmias. Plasma LA Concentration Rising

  • │
  • ┌──────────────────────────────┴──────────────────────────────┐
  • ▼ ▼
  • Central Nervous System (CNS) Cardiovascular System (CVS)

1. Initial Cortical Excitation: 1. Electrophysiological Depression:

  • Circumoral / perioral numbness - PR interval prolongation
  • Metallic taste in mouth - QRS widening
  • Tinnitus and auditory distortion - Sinus bradycardia & heart blocks
  • Agitation, restlessness, slurred speech
  • │ │
  • ▼ ▼

2. Severe Excitation: 2. Contractile Depression:

  • Muscle twitching and fasciculations - Profound peripheral vasodilation
  • Generalized tonic-clonic seizures - Severe hypotension
  • │ │
  • ▼ ▼

3. CNS Depression: 3. Cardiovascular Collapse:

  • Loss of consciousness, coma - Ventricular arrhythmias (VF/pVT)
  • Respiratory depression & arrest - Asystolic cardiac arrest
  • Emergency Management Protocol for LAST

Immediate Cessation & Airway Support:

Cease injection immediately and summon emergency assistance (call 999).

Administer 100% high-flow oxygen via a non-rebreather reservoir mask (15 L/min). Hyperventilation prevents respiratory acidosis; acidosis increases the free ionized fraction of local anaesthetics and exacerbates CNS toxicity.

Seizure Management:

Terminate tonic-clonic convulsions promptly to prevent metabolic acidosis. Administer Buccal Midazolam 10 mg (or IV Midazolam 2–5 mg if venous access is established).

Advanced Resuscitation & Intravenous Lipid Emulsion Therapy:

If cardiovascular compromise or cardiac arrest develops, initiate high-quality chest compressions immediately.

Specific Antidote: Intravenous 20% Lipid Emulsion (Intralipid):

Mechanism ("Lipid Sink"): The circulating lipid droplets establish a separate intravascular hydrophobic phase that sequesters lipophilic local anaesthetic molecules away from cardiac myocytes and brain tissue, restoring sodium channel conductances.

Administration Regimen: Administer an initial IV bolus of 1.5 mL/kg of 20% Intralipid over 1 minute (~100 mL for a 70 kg adult), followed immediately by a continuous IV infusion of 0.25 mL/kg/min . If cardiovascular stability is not restored, the bolus can be repeated up to two times at 5-minute intervals, and the infusion rate increased to 0.5 mL/kg/min.

Resuscitation Modifications: In LAST-induced cardiac arrest, reduce individual adrenaline boluses during CPR to < 1 mcg/kg <1\text{ mcg/kg} < 1 mcg/kg (avoid large 1 mg boluses which worsen arrhythmias), and avoid vasopressin, calcium channel blockers, and beta-blockers.